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Guidelines and Guidance
Introduction
Scientific publications are one of the most important outputs 
of any research, as they are the primary means of sharing 
the findings with the broader research community. The 
quality and relevance of research is mostly judged through 
the published report, which is often the only public record 
that the research was done. Unclear reporting of a study’s 
methodology and findings prevents critical appraisal of 
the study and limits effective dissemination. Inadequate 
reporting of medical research carries with it an additional 
risk of inadequate and misleading study results being used by 
patients and health care providers. Patients may be harmed 
and scarce health care resources may be expended on 
ineffective health care treatments through such inadequate 
reporting. There is a wealth of evidence that much of 
published medical research is reported poorly [1–12]. Yet a 
good report is an essential component of good research.
Reporting guidelines, such as the CONSORT 
(Consolidated Standards of Reporting Trials) Statement 
for reporting the findings of randomised controlled trials 
[13], can lead to important improvements in the quality and 
reliability of published research. Since the development of 
the CONSORT Statement in 1996, several other guidelines 
have been developed relating to other types of research 
studies. Examples include QUOROM (for meta-analyses of 
randomised trials) [14], STARD (Standards for Reporting of 
Diagnostic Accuracy Studies) [15], STROBE (Strengthening 
the Reporting of Observational Studies in Epidemiology) 
[16], and REMARK (Reporting Recommendations for 
Tumour Marker Prognostic Studies) [17]. 
At present, no coordination or focused collaboration in 
the development of reporting guidelines exists as there is in, 
for example, the clinical practice guidelines field. Guideline 
development methods vary greatly. Dissemination and 
implementation of reporting guidelines relies mostly on passive 
publication of the guidelines, occasionally accompanied by 
editorials. Reporting guidelines are not routinely used on a 
large scale, and their potential is not being fully realised. 
To remedy this situation, the National Knowledge Service 
of the UK National Health Service provided funds to set 
up the EQUATOR Network (Enhancing the Quality and 
Transparency of Health Research; http://www.equator-
network.org/). This new initiative seeks to improve the 
quality of scientific publications by promoting transparent 
and accurate reporting. The Network provides resources 
and training relating to the reporting of health research 
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Summary points
sÈ (IGH
QUALITYÈREPORTINGÈINÈSCIENTIFICÈPUBLICATIONSÈISÈCRUCIALÈFORÈ
dissemination and implementation of research findings. 
sÈ 2EPORTINGÈGUIDELINESÈSUCHÈASÈTHEÈ#/.3/24È3TATEMENTÈCANÈ
improve accuracy and reliability of research reports, providing 
that they are themselves developed to high standards. 
sÈ 4HISÈSURVEYÈOFÈDEVELOPERSÈOFÈÈGENERICÈREPORTINGÈGUIDELINESÈ
showed that: development methods were broadly similar 
but varied in important details; development usually took a 
long time; only half of the guideline developers had strategies 
for dissemination and implementation of their guidelines; 
and securing sufficient funding to develop, evaluate, and 
disseminate guidelines was a major problem.
sÈ 4HEREÈISÈAÈNEEDÈTOÈHARMONISEÈMETHODSÈUSEDÈINÈTHEÈ
development of reporting guidelines and concentrate more 
on their active promotion, implementation, and evaluation.
sÈ 4HEÈ%15!4/2È.ETWORKÈHTTPWWWEQUATOR
NETWORKORG	ÈISÈ
AÈNEWÈINITIATIVEÈTHATÈAIMSÈTOÈIMPROVEÈTHEÈQUALITYÈOFÈSCIENTIFICÈ
literature. It provides resources and training on reporting of 
health research and assists in the development, dissemination, 
and implementation of reporting guidelines.
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Table 1. Characteristics of Reporting Guideline Development Processes (Summary of Responses to Multiple-Choice Questions)
Questions and Responses Number of Reporting Guidelines % (n = 30) 
What motivated the work on this guideline?
0OORÈQUALITYÈOFÈREPORTING 26 87
Development of guidelines in other areas 9 30
Other (as the only answer)  4 13
How was the relevant evidence identified?
Asking group members 24 80
Electronic searches of the main databases 23 77
Own collection of published literature 23 77
Hand searches of published literature 18 60
Searching for ongoing studies 7 23
Searching for unpublished studies 5 17
Method used for developing guideline recommendations
Informal consensus   23a 77
Formal consensus 62 0
Was the draft guideline shared with a broader circle of experts for comments before being finalised?
Shared with the entire working group and with those who contributed in any way to the 
development of the guideline
22b 73
Shared with an entirely distinct, broader circle of experts outside the working group 17 57
Not shared at all  1  3
How was the guideline summarised?
Text 27 90
Checklist 24 80
Flowchart  62 0
Was specific funding available for the following steps?
Meeting costs 18 60
Travel costs 15 50
No funding available 10 33
Administrative support 6 20
Researcher time  41 3
Source of the funding
Grant from non-profit organisation 14 47
Own budget 11 37
Pharmaceutical industry support 5 17
Government 26
How was your guideline disseminated?
Publication in one peer-reviewed journal 19c 63
Conference presentation 19 63
Published on other Web sites 15 50
Lectures and talks for potential users 12 40
Publication in more than one peer-reviewed journal 10 33
Web site created for the guideline 10 33
Have you used any implementation strategies to increase uptake of the guideline by authors?
Yes 13d 43
No  15 50
Have you used any implementation strategies to increase uptake of the guideline by journals?
Yes 12e 40
No  17 57
Have you (or anyone else) performed any formal evaluation of the uptake of the guideline by journals?
Yes 5b 17
No  24 80
Have you (or anyone else) performed any formal evaluation of the impact of the guideline on the quality of reporting?
Yes 5b 17
No  24 80
Has the guideline been formally endorsed by any organisations?
Yes 17f 57
No  11 37
Do you think your guideline will need updating?
Yes  25b 83
No  41 3
Have you consulted any other members from your guideline working group in answering these questions? 
Yes 10 33
No  20 67
aOnEÈGUIDELINEÈUSEDÈBOTHÈTWOÈGUIDELINESÈWEREÈDEVELOPEDÈBYÈONEÈPERSONÈQUESTIONÈNOTÈRELEVANT	È
bOne guideline no response.
c/NEÈGUIDELINEÈNOÈDEDICATEDÈJOURNALÈPUBLICATIONÈPUBLISHEDÈINÈHEALTHÈTECHNOLOGYÈASSESSMENTÈREPORTÈANDÈSUBSEQUENTÈBOOK
dOne guideline ongoing (planned dissemination strategies); one guideline no response.
eTwo guidelines that did not use any specific strategy are going to discuss the issue at their next meeting; one guideline no response.
fOne guideline no response; one guideline “not known”.
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and assists in the development, dissemination, and 
implementation of reporting guidelines.
The first project of the EQUATOR Network was to: (1) 
identify all available guidelines for reporting health research 
studies and (2) survey the authors of these guidelines to gather 
details about their development methodology, dissemination 
and implementation strategies, and problems encountered 
during those processes. Given sparse information on the 
benefits of guidelines [18,19], we also asked authors about 
published and unpublished evaluations of impact. This article 
reports the findings of our survey.
Methods
Identification of studies. We identified published reporting 
guidelines through systematic searches of MEDLINE, 
EMBASE, The Cochrane Library, CINAHL, PsycINFO, Web 
of Science, and general Internet resources through a Google 
search. File S1 shows the MEDLINE search strategy. We also 
searched reference lists of relevant articles and personal 
collections of papers. We encountered various terms used for 
reporting guidance across the literature, such as reporting 
guidelines, recommendations, and standards. For the 
purposes of this article we use the term “guideline” without 
any implication regarding the methodology used for the 
guidance development.
Our aim was to initially identify all available guidance for 
reporting of scientific studies in health research. We deliberately 
set very broad inclusion criteria: any guidelines published in 
the period 1996 to 2006 with the objective of improving the 
reporting of research studies relating to health. One reviewer 
(IS) screened the records and selected potentially relevant 
papers. These full-text articles were retrieved and evaluated 
for inclusion by two reviewers (IS and DGA). Any instruments 
designed for the evaluation of study quality, although closely 
related to reporting guidelines, were not included.
From the starting point of these very broad inclusion 
criteria, we then narrowed our selection to include only very 
broad, generic guidelines on reporting medical research, and 
to exclude more specialised or narrow guidelines. In total, 37 
reporting guidelines met our criteria and were eligible for the 
survey (File S2).
Questionnaire design. We aimed to survey the 
developers of these 37 guidelines in order to gain insight 
into their development processes. We designed a four-
page, 25-item questionnaire covering the main aspects of 
reporting guideline development: the characteristics of the 
development group; motivation; guideline development 
process; dissemination, uptake, and impact of the guideline; 
funding; and problems experienced during the development 
process. Where possible we included multiple options and 
encouraged respondents to tick all answers that applied; some 
open questions required descriptive answers. 
The questionnaire was e-mailed, together with a 
covering letter describing the purpose of the project, to 
the corresponding author of the reporting guideline. Two 
reminders were sent to non-respondents, and when no 
response was received another author was approached.
Data collection and analysis. The answers to multiple-
choice questions were summarised as percentages of the 
whole sample; the answers to open descriptive questions 
were summarised in brief statements. Here we present our 
aggregate findings.
Our Findings
Characteristics of reporting guidelines identified from the 
literature. The 37 eligible guidelines (File S2) were very 
diverse, ranging from well-known general guidelines for 
reporting results of specific types of research studies, such 
as CONSORT for randomised trials [13] and STARD for 
diagnostic accuracy studies [15], to the first attempts to 
harmonise reporting of a particular aspect of research, such 
as the search strategy for systematic reviews [20].
Two of the identified guidelines provided standards for 
reporting data (MIAME [Minimum Information about a 
Microarray Experiment] for microarray-based expression 
gene data [21] and MIAPE [Minimum Information about a 
Proteomics Experiment] for proteomics experiments [22]). 
The CONSORT Statement has probably been the 
most influential reporting guideline published thus 
far. In our sample of 37 guidelines, six were extensions 
of the CONSORT Statement [23–28]; two provided 
recommendations complementary to CONSORT [29,30]; and 
ten referred to or claimed to be influenced by the CONSORT 
Statement development [14–17,31–36]. 
Survey results. We received responses from 30 of 37 
guideline developers (81% response rate). Most respondents 
answered all questions. Where some questions were left 
unanswered, this is indicated. Ten respondents (33%) 
consulted a colleague when completing the questionnaire. 
Table 1 summarises responses to multiple-choice questions 
related to basic aspects of reporting guideline development 
processes.
Guideline development group. Most of the surveyed 
guidelines were developed by an international 
multidisciplinary group (22 of 30; 73%); only two guidelines 
were developed by one person. The median number of 
people participating in the guideline development was 22 
(range: 1–118). Nineteen groups established a core (writing) 
group that had a median number of seven people (range: 
3–24). The membership of the working groups reflected the 
guidelines’ scope—statisticians, journal editors, clinicians, 
and epidemiologists were included in most development 
groups. Some groups included medical writers, social 
scientists, information specialists, health economists, and 
Box 1. Steps Used in the Development of 
Reporting Guidelines
sÈ 'ENERATINGÈIDEASCHECKLISTÈITEMSÈTHROUGHÈTELEPHONEÈ
conversations, face-to-face meetings, and guideline topics 
mandated by professional association)
sÈ ,ITERATUREÈREVIEWÈSYSTEMATICÈREVIEW	
sÈ #RITICALÈAPPRAISALÈOFÈIDENTIFIEDÈEVIDENCEÈ
sÈ 3HARINGÈRELEVANTÈEVIDENCEÈWITHÈAÈLARGERÈTEAM
sÈ !GENDAÈFORÈDISCUSSIONGENERATINGÈITEMS
sÈ $ISCUSSIONÈOFÈITEMS
sÈ !GREEMENTÈONÈPHRASINGÈANDÈEXPLANATIONÈOFÈITEMS
sÈ 7RITINGÈTHEÈFIRSTÈDRAFT
sÈ #IRCULATIONÈFORÈCOMMENTS
sÈ )NCORPORATIONÈOFÈCOMMENTS
sÈ 2EPEATINGÈPREVIOUSÈTWOÈSTEPSÈUNTILÈREACHINGÈCONSENSUSÈ
among groupPLoS Medicine  |  www.plosmedicine.org 0872 June 2008  |  Volume 5  |  Issue 6  |  e139
representatives of the pharmaceutical industry. One group 
also invited representatives of grant funding agencies; another 
group invited a patient representative. The guidelines 
providing standards for reporting data also included relevant 
bioinformatics experts and software vendors. 
Motivation for the guideline development. Poor quality 
of reporting was the most common motivating factor for the 
guideline development (87%), followed by the influence of 
other reporting guidelines being developed (30%). Among 
other contributing factors were difficulties encountered in 
critical appraisal and systematic reviews; lack of reporting 
standards in a particular field; and concerns about 
inappropriate publication processes. Two guidelines were 
commissioned by professional organisations and one was 
developed at the request of a medical journal. 
Guideline development processes. The guidelines were 
developed in various ways. The main activities involved in 
guideline development are summarised in Box 1. Not all 
guidelines, however, went through all the stages or proceeded 
in that order. 
Some of the guideline groups started their work from 
scratch while others adapted existing guidelines for a 
new or more specialised research field. All the groups 
but one made an effort to collect relevant evidence to 
support the recommendations; some used extensive 
comprehensive literature searches, while others retrieved 
the relevant literature in a less formal way (e.g., personal 
article collections of group members, asking experts in 
the field). Acquired evidence (the full-text papers or 
summary statements with extracted data) was shared with 
the group through e-mail, postal mail, or Web site posting. 
Most groups (90%) organised one or more face-to-face 
meetings at various stages of the guideline development: 
either at the very beginning of the process to generate 
ideas, or later to discuss pre-prepared evidence summaries 
or draft guidelines. Meetings usually had both small group 
working sessions and plenary discussion sessions. Reporting 
recommendations were mostly developed through informal 
consensus (77%). Six groups used formal consensus 
methods (three used a modified Delphi technique, one used 
focus groups with a modified Delphi technique, and two did 
not specify the method). Draft guidelines were shared with 
the entire working group for comment. Seventeen groups 
(57%) also sought comments on the draft guideline from 
a distinct, broader circle of experts outside the working 
group. 
Reporting recommendations were summarised in the 
form of text (90%) and/or checklists (80%; with three 
guidelines being a checklist only). Six groups (20%) also 
included a flow diagram and one guideline related to 
data reporting standards included features specific for 
this type of report (formal data representation, controlled 
vocabularies). 
On average, the guidelines took 20 months to complete 
(range: 3–62 months) and another 11 months, on average, to 
publish (range: 0–30 months). 
Twenty-five respondents (83%) felt that their guidelines 
will need to be updated in the future. 
Dissemination, uptake, and impact of the guidelines. 
Publication in a peer-reviewed journal and presentation 
at conferences were the most frequently used means for 
guideline dissemination. Ten groups negotiated multiple 
journal publications to ensure wider and quicker spread. The 
Internet was also used for dissemination (Table 1). 
Medical journals played an active role in the dissemination 
and implementation of one third of the surveyed guidelines 
by publishing commentaries endorsing the guidelines or 
providing Web links or citations to the reporting guidelines in 
their “Instructions to Authors”. 
About half of the guideline groups recognised the need to 
develop implementation strategies to increase the uptake of 
the guideline by authors and journals (Table 1). Strategies 
used included publication of supporting articles, letters, 
commentaries, and editorials; development of a detailed 
“explanation and elaboration” document; translations; free 
availability from the Web sites (including journals’ sites); 
inclusion in “Instructions to Authors” of various journals; and 
organising courses and workshops promoting the use of the 
reporting guideline. 
Solicitation of support from potentially relevant partners, 
including journal editors, funding agencies, professional 
organisations and societies, or where relevant, software 
vendors, was seen as one of the crucial aspects of successful 
implementation. Active collaboration with journals was 
recognised in particular—editors were often invited to 
participate in the development of the guidelines (25 groups, 
83%). Some groups also asked for the guideline to be 
endorsed by the journal and included in its “Instructions to 
Authors” (six groups, 20%). One group also approached 
journals to discuss how the guideline could be used efficiently 
within the editorial process.
Guideline uptake by medical journals was formally 
evaluated for five guidelines (17%), either by a survey of 
“Instructions to Authors” and/or by a count of journals that 
had adopted the guideline. The impact of guidelines on the 
quality of reporting was evaluated in five cases. 
Problems experienced during the guideline development 
process. The major problems encountered are listed in 
Box 2. Lack of sufficient funding and time constraints were 
identified as the most pressing issues. One third of the 
guidelines were developed without any dedicated funding 
(Table 1). Where funding was available, it was provided 
mostly to cover costs of the meetings and associated travel 
expenses. Only four groups had secured funding for 
research-related activities such as searching for evidence, 
data synthesis, and writing. Seven groups highlighted the 
consequences of inadequate funding as one of the main 
obstacles in guideline development.
Box 2. Major Problems Experienced During the 
Guideline Development Process
sÈ ,ACKÈOFÈSUFFICIENTÈFUNDING
sÈ 4IMEÈCONSTRAINTSÈ
sÈ 7ORKÈNOTÈCONSIDEREDÈASÈACADEMICÈRESEARCHÈ
sÈ ,ACKÈOFÈEVIDENCEÈONÈWHICHÈTOÈBASEÈTHEÈGUIDELINES
sÈ $ECISIONSÈONÈTERMINOLOGYÈFORÈTHEÈGUIDELINES
sÈ 2ELUCTANCEÈOFÈJOURNALSÈTOÈPUBLISHÈGUIDELINES
sÈ 7ORKINGÈGROUPÈPERSONNELÈCHANGES
sÈ %XISTENCEÈOFÈMOREÈTHANÈONEÈREPORTINGÈGUIDELINEÈINÈAÈSINGLEÈ
area of endeavour) 
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A closely related problem was the perception that 
development of reporting guidelines was not considered as 
research in some academic institutions. The survey participants 
also mentioned problems with logistics, such as managing the 
large number of people involved in the guideline development 
or assembling the international team with almost no funding.
Discussion
Reporting guidelines have the potential to improve the 
quality of reporting and consequently the quality of research 
[18,19]. But such guidelines could conceivably have 
downsides as well—for example, they might encourage some 
authors to simply report the information required by the 
guidance regardless of whether it was actually part of the 
study’s conduct. 
Development of reporting guidelines should follow robust 
methodology if they are to be widely accepted by the relevant 
scientific and health care publishing community. 
Our survey found evidence of a widespread lack of 
funding for developing guidelines. Some of the national 
health research funding agencies have begun to recognise 
this problem. For example, the CONSORT group recently 
obtained a five-year funding grant from the UK National 
Health Service’s Research & Development Methodology 
Programme for partial support of its activities, but such 
funding is rare. Although our survey did not enquire about 
the exact costs of developing reporting guidelines, we 
estimate that the costs might be in the region of UK£50,000 
for a single appropriately developed consensus reporting 
guideline. If reporting guidelines are to remain evidence-
based, they need to be regularly updated, which also requires 
funding. As yet, only one guideline team (the developers of 
CONSORT) have published a revision, although 25 (83%) 
others recognised the need to do so in due course. 
When developing reporting guidelines, it is important to 
include an evaluation component. In our survey, evaluations 
of the uptake of the guideline by journals and/or evaluation 
of the guideline’s impact on the quality of reporting had been 
attempted for only eight (27%) guidelines. Even though the 
CONSORT Statement is widely accepted, only 36 (22%) of 
167 journals surveyed by Altman [37] referred to CONSORT 
in their guidance to authors, and many used ambiguous 
language in describing what was expected from authors or 
referred to an old version of the Statement. 
Information gathered from the survey shows a need to 
harmonise methods used in the development of reporting 
guidelines. It is also important to evaluate the impact of 
guidelines. Because this type of evaluation research is 
difficult to fund, such studies might have a better chance 
of receiving support if they are undertaken collaboratively 
by a combination of research funders, authors, editors, and 
publishers. Such collaboration might also reduce the risk of 
bias inherent in self-evaluations. 
In addition to the 37 guidelines we targeted in our survey, 
we also identified a considerable number of specialised 
reporting guidelines providing recommendations for 
reporting specific medical conditions or procedures (see File 
S1). Although we excluded these specialised guidelines from 
our survey, we recognise their importance and plan to engage 
their developers in the EQUATOR Network.
We hope that EQUATOR will act as an “umbrella” 
organisation, bringing together developers of reporting 
guidelines, medical journal editors and peer reviewers, 
research funding bodies, and other key stakeholders with 
a mutual interest in improving the quality of research 
publications and research itself. Our goal is to improve the 
quality and reliability of the medical literature by promoting 
the transparent and accurate reporting of health research. 
We will actively promote the use of reporting guidelines 
among journals, as their effectiveness critically depends on 
support from editors of influential medical journals. 
Poor reporting cannot be seen as an isolated problem that 
can be solved by targeting only one of the parties involved 
in disseminating research findings, be it authors, editors, or 
peer reviewers. A well-coordinated effort, with collaboration 
between the research and publishing communities, strongly 
supported by research funders, will likely have a better chance 
of leading to improved reporting of health research. In turn, 
better reporting is likely to influence the quality and impact 
of future research.  
Supporting Information
File S1. Search strategy
Found at doi:10.1371/journal.pmed.0050139.sd001 (35 KB DOC).
File S2. Reporting guidelines included in the survey
Found at doi:10.1371/journal.pmed.0050139.sd002 (42 KB DOC).
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